Thank you, Adrian and Andre. We are excited about the progress of our partnerships, which are positively impacting our financial position. In particular, dollars 47,000,000 have been triggered so far under the AstraZeneca joint research and collaboration agreement, of which $25,000,000 upfront and $22,000,000 reached development milestones, in addition to reimbursement of research costs incurred. In our financials, the cash, cash equivalents, restricted cash and fixed term deposits classified as current financial assets as of September 30, 2024, amount to $264,000,000 compared to $156,000,000 as of December 31, 2023. This $108,000,000 increase is mainly due to $140,000,000 cash received from AstraZeneca as part of the 2nd tranche of its equity investment in Selectus, dollars 16,000,000 cash received from the European Investment Bank, EIB, pursuant to the disbursement of the €15,000,000 tranche B under the finance contract with EIB, dollars 8,000,000 of cash in from our financial investments, dollars 27,000,000 of cash in from our revenue, partially offset by cash payments from Selectus to suppliers of $42,000,000 including $30,000,000 to R and D suppliers and $12,000,000 to SG and A suppliers selectus wages, bonuses and social expenses paid of $32,000,000 the payments of lease debt of $8,000,000 and the repayment of the PGE loan of $4,000,000 You're invited to refer to our press release for figures related to consolidated net loss attributable to shareholders of Selective for the 9 months ended September 30, 2024.